Clinical efficacy and safety of BRAF/MEK inhibitors for anaplastic thyroid cancer; An observational study of ATC Research Consortium of Japan.

Clinical efficacy and safety of BRAF/MEK inhibitors for anaplastic thyroid cancer; An observational study of ATC Research Consortium of Japan. - BRAVE study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031240365

Enrollment

200

Registered

2024-10-03

Start date

2024-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaplastic thyroid cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have been histologically diagnosed with anaplastic thyroid cancer 2. Patients aged 20 years or older

Exclusion criteria

Exclusion criteria: 1. Patients with active multiple primary cancers (lesions equivalent to carcinoma in situ or intramucosal cancer that are deemed curable by local treatment will not be included in active concurrent cancers) 2. Patients who are deemed ineligible for this study by the researchers 3. Patients who refuse to provide data for this study

Design outcomes

Primary

Measure	Time frame
12-month survival rate in patients treated with BRAF inhibitors	—

Secondary

Measure	Time frame
1. Prevalence of BRAF gene mutations in ATC cases in Japan 2. Evaluation of prognostic factors in all cases 3. Efficacy and safety of BRAF inhibitors in cases treated with BRAF inhibitors 4. Evaluation of surgery in cases treated with BRAF inhibitors	—

Contacts

Public ContactHaruhiko Yamazaki

Yokohama City University Medical Center

yamazaki.har.zo@yokohama-cu.ac.jp+81-45-261-5656

Outcome results